MNG441
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.322
- KRAS_SIGNALING_DN+0.290
- MYOGENESIS+0.185
- ALLOGRAFT_REJECTION+0.155
- SPERMATOGENESIS+0.111
- COAGULATION+0.051
- APICAL_SURFACE+0.026
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.009
- KRAS_SIGNALING_UP-0.031
- WNT_BETA_CATENIN_SIGNALING-0.037
Top 10 suppressed
- MYC_TARGETS_V1-0.586
- PROTEIN_SECRETION-0.579
- MTORC1_SIGNALING-0.536
- UNFOLDED_PROTEIN_RESPONSE-0.528
- MYC_TARGETS_V2-0.515
- MITOTIC_SPINDLE-0.487
- E2F_TARGETS-0.483
- OXIDATIVE_PHOSPHORYLATION-0.472
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.462
- G2M_CHECKPOINT-0.460
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1217 | — | — | 0.971 |
| 2 | SRR1366141 | GTEX | — | 0.955 |
| 3 | MNG1259 | — | — | 0.952 |
| 4 | SRR1313951 | GTEX | — | 0.951 |
| 5 | MDT-AP-1143 | Med | Medulloblastoma | 0.949 |
| 6 | MNG597 | — | — | 0.944 |
| 7 | MNG1092 | — | — | 0.944 |
| 8 | BS_23W9EPFE | Ganglioglioma | — | 0.942 |
| 9 | 08e3d239-3d8a-4eee-9e08-ac2bcb3f2619 | — | — | 0.941 |
| 10 | SRR1419714 | GTEX | — | 0.941 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.322 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.185 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.155 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.111 | Inavolisib | — uncovered |
| COAGULATION | 0.051 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.026 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.009 | Inavolisib | — uncovered |